IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright 25^th Annual Global Investment Conference on Wednesday, September 13, 2023 at 2:00 p.m. ET.

Read more at globenewswire.com